We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+35.5%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$614M
AUM Growth
+$229M
Cap. Flow
+$94.5M
Cap. Flow %
15.38%
Top 10 Hldgs %
48.42%
Holding
129
New
38
Increased
24
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$12.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.48M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.95M
4
AZN icon
AstraZeneca
AZN
+$6.54M
5
NICE icon
Nice
NICE
+$5.73M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$50.1M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.3M
3
GILD icon
Gilead Sciences
GILD
+$6.5M
4
GSK icon
GSK
GSK
+$6.39M
5
AGN
Allergan plc
AGN
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 57.48%
2 Technology 4.42%
3 Communication Services 1.38%
4 Industrials 1.09%
5 Consumer Discretionary 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
51
CALL
Gilead Sciences
GILD
$162B
$3.1M 0.51%
39,200
+38,700
+7,740% +$3.14M
ACOR
52
DELISTED
Acorda Therapeutics
ACOR
$3.09M 0.5%
1,233
+416
+51% +$1.24M
ENDP
53
DELISTED
Endo International plc
ENDP
$3.02M 0.49%
150,000
– –
KYNB
54
Kyntra Bio
KYNB
$27.2M
$3.02M 0.49%
5,828
+2,400
+70% +$1.13M
ALDX icon
55
Aldeyra Therapeutics
ALDX
$92.9M
$2.89M 0.47%
368,500
– –
DBVT
56
DBV Technologies
DBVT
$799M
$2.87M 0.47%
7,906
+1,845
+30% +$641K
KITE
57
DELISTED
Kite Pharma, Inc.
KITE
$2.79M 0.45%
50,000
– –
AAPL icon
58
CALL
Apple
AAPL
$4.54T
$2.76M 0.45%
+74,000
New +$1.96M
SNA icon
59
Snap-on
SNA
$21.2B
$2.75M 0.45%
+18,130
New +$2.8M
BOLD
60
DELISTED
Audentes Therapeutics, Inc
BOLD
$2.67M 0.44%
+150,000
New +$2.28M
FWP
61
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.55M 0.42%
17,357
– –
SNDX icon
62
Syndax Pharmaceuticals
SNDX
$1.69B
$2.52M 0.41%
+166,310
New +$2.19M
GNMX
63
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2.51M 0.41%
450,000
– –
ARAV
64
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.45M 0.4%
+33,333
New +$2.41M
MRNS
65
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.44M 0.4%
335,147
+42,486
+15% +$287K
ATXS
66
DELISTED
Astria Therapeutics
ATXS
$2.39M 0.39%
6,466
+3,079
+91% +$811K
DERM
67
DELISTED
Dermira, Inc.
DERM
$2.37M 0.39%
70,000
– –
VTGN icon
68
VistaGen Therapeutics
VTGN
$9.89M
$2.26M 0.37%
18,137
+8,334
+85% +$905K
SBUX icon
69
Starbucks
SBUX
$120B
$2.25M 0.37%
+41,600
New +$2.33M
EGLT
70
DELISTED
Egalet Corporation
EGLT
$2.23M 0.36%
292,500
– –
AAP icon
71
Advance Auto Parts
AAP
$3.35B
$2.17M 0.35%
14,569
-13,093
-47% -$2.09M
ADXS
72
DELISTED
Advaxis Inc
ADXS
$2.14M 0.35%
+13,333
New +$2.17M
ARDX icon
73
Ardelyx
ARDX
$1.22B
$1.96M 0.32%
+151,813
New +$1.59M
TRIL
74
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.96M 0.32%
132,300
– –
XENE icon
75
Xenon Pharmaceuticals
XENE
$6.06B
$1.85M 0.3%
+228,029
New +$1.76M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sphera Funds Management held 129 positions worth $614M, up 59% from $385M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sphera Funds Management deployed $94.5M of net new capital in Q3 2016, opening 38 new positions and adding to 24 existing holdings. Its largest new stake was Sarepta Therapeutics: 263,047 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 77% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Shire pic, an estimated $50.1M trimmed.

  • Sphera Funds Management's largest Q3 2016 buy was Sarepta Therapeutics: 263,047 shares worth $16.2M.
  • Sphera Funds Management added most to Merck in Q3 2016, an estimated $12.3M increase.
  • Sphera Funds Management's biggest Q3 2016 reduction was Shire pic, cutting an estimated $50.1M.
  • Sphera Funds Management fully exited GSK in Q3 2016, selling an estimated $6.39M.
  • Sphera Funds Management's ten largest holdings make up 48% of its $614M portfolio in Q3 2016.
  • Sphera Funds Management opened 38 new positions and closed 23 in Q3 2016.
  • Sphera Funds Management's portfolio value rose 59% quarter-over-quarter to $614M.

Based on Sphera Funds Management's 13F filing for Q3 2016, filed 14 Nov 2016.